1-5 of 5
Paul Van Der Valk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Frank W.G. Leebeek, Karina Meijer, Michiel Coppens, Peter Kampmann, Dr. Klamroth, Paul van der Valk, Paul E. Monahan, Karen Pinachyan, Sandra LeQuellec, Wolfgang Miesbach
Journal: Blood
Blood (2024) 144 (Supplement 1): 3578.
https://doi.org/10.1182/blood-2024-198379
Published: 2024
Journal Articles

Adult Patients with Hemophilia B and with a History of Chronic HCV/HBV Infection Receiving Liver-Directed Gene Therapy Demonstrated Long-Term Bleeding Protection and Sustained FIX Activity: Efficacy and Safety Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec

Annette von Drygalski, Niamh O'Connell, Peter Verhamme, Karina Meijer, Paul van der Valk, Rashid Saeed Kazmi, Priyanka Raheja, Nicholas Galante, Sandra LeQuellec, Rachel Church, Samantha Lucas, Giancarlo Castaman, Paul Monahan
Journal: Blood
Blood (2023) 142 (Supplement 1): 2258.
https://doi.org/10.1182/blood-2023-188921
Published: 2023
Journal Articles

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Steven Pipe, Paul van der Valk, Peter Verhamme, Peter Kampmann, Frank W.G. Leebeek, Michiel Coppens, Karina Meijer, Priyanka Raheja, Nigel S. Key, Nathan Visweshwar, Guy Young, Richard S. Lemons, Robert Klamroth, Wolfgang Miesbach, Jan Astermark, Niamh O'Connell, Rashid Saeed Kazmi, Nicholas Galante, Sandra LeQuellec, Paul Monahan, Cedric R. Hermans
Journal: Blood
Blood (2023) 142 (Supplement 1): 1055.
https://doi.org/10.1182/blood-2023-187624
Published: 2023
Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-6.
https://doi.org/10.1182/blood-2020-143560
Published: 2020
Journal Articles

CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor

Hedwich F. Kuipers, Paula J. Biesta, Lisette J. Montagne, Elise S. van Haastert, Paul van der Valk, Peter J. van den Elsen
Journal: Blood
Blood (2008) 112 (5): 1610–1619.
https://doi.org/10.1182/blood-2008-01-135111
Published: 2008